🔗 Share this article Social Media Influencers Fueling Parallel Market for Unlicensed Weight-Loss Drug A shadow market for unapproved slimming medications is propelled by TikTok fitness influencers and sellers on messaging platforms, based on recent findings. Investigational Drug Gaining Popularity Via Social Media Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Followers are encouraged to contact these accounts directly for supplier links, while also obtaining discount codes. Active Trade on Messaging Platforms Additionally, a flourishing market exists on Telegram, where groups with numerous of members share “before and after” images, administration instructions and assertions of next-day UK delivery. Vendors market the substance there before redirecting buyers to WhatsApp for transactions. Learning About The Experimental Drug Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The treatment affects three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help individuals lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic. Healthcare Professionals Express Concerns However, doctors and pharmacists have cautions that the distribution of what is still an unlicensed drug in the United Kingdom is a cause for concern and could lead to users administering substances of unknown origin. Several professionals said the popularity for the experimental drug could be connected to the increasing price of approved slimming products such as Mounjaro. Regulatory Position and Implementation Marketing retatrutide on TikTok or Telegram is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the British medical regulations. Some content creators attempt to circumvent the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but promotion and distribution can still breach medicines, marketing, and consumer laws, potentially leading to fines, legal action or imprisonment. Service Response and Content Elimination According to the social media company, the platform has removed violative content and banned associated keywords and search suggestions. The organization said it was committed to keeping the platform secure and investing in enhancing compliance measures. Digital Trading Activities Research also found communities with up to nine thousand participants selling retatrutide using the platform's built-in search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up groups with numerous of members, filled with photos of weight loss, positive testimonials and detailed guides for mixing or administering at home. After moments of entering one group, a vendor shared WhatsApp details, where the majority of transactions take place. The vendor provided an instruction manual and promised shipping within 48 hours. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one inquired about body mass, health issues or previous experience. Item Details and Costs Within these communities, messages display black plastic parcels with postal service labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.” Customers can select between powder vials, prepared at home with purified liquid, or pre-filled injectors usually priced at £160 for 20mg. When asked how much time a injector should last, sellers give contradictory answers ranging from a several days to “depends on your body”. Platform Moderation and Security Actions A spokesperson for Telegram said it regularly moderated harmful material on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”. Medical Expert Warnings “People are administering substances they can’t verify. Although the research behind retatrutide is valid, these digital versions may not contain what they advertise,” said a pharmacy expert, the head of pharmacy at a pharmacy service. Dr Crystal Wyllie of an online medical service connected the surge in demand to recent price rises for approved weight-loss medications such as Mounjaro. “With costs rising, individuals are using online platforms. But counterfeit treatments are extremely dangerous. You cannot know what’s inside or whether the environment they were produced in was clean,” she said. Her staff has already encountered patients injured by personal administration from unconfirmed sources. “We understand the frustration, but purchasing from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These materials could be contaminated or improperly measured.” Producer Position A representative from Eli Lilly stated the substance was in third stage clinical trials and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this point no one can sell [it] for human use,” they said, noting that any item “misleadingly claiming itself as a Lilly experimental product not yet authorized … may expose patients to potentially significant health risks”.